IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

Fetal Hemoglobin Induction as an Advanced Therapeutic Strategy in Beta-Hemoglobinopathies

Krushna M. Babar[1], Dr. Ravi U. Kurhade[2], Dr. Amol D. Pagar[3], Amol S. Dhakpade[4], Nishinandan M. Shinde[5]

[1]M. Pharm Final Year Student, Department of Pharmacology
[2]Principal, Department of Pharmaceutics
[3]Professor, Department of Pharmacology
[4]Assistant Professor, Department of Pharmachemistry
[5]Assistant Professor, Department of Pharmaceutics
MDA School of Pharmacy, Kolpa, Latur, Maharashtra
krishnababar1244@gmail.com

Abstract: *Fetal hemoglobin induction is one of the most biologically validated approaches for modifying sickle cell disease and beta-thalassemia. HbF reduces HbS polymerization, improves globin-chain balance and has been supported by natural genetic modifiers, hydroxyurea therapy and modern gene-editing strategies. This review summarizes the molecular basis of HbF protection, the regulatory network controlling the fetal-to-adult globin switch, established and investigational pharmacological inducer classes, formulation and safety constraints, and Quality-by-Design considerations for candidate evaluation. The review emphasizes that HbF induction must be assessed through integrated endpoints including HbF protein, HBG1/HBG2 transcripts, F-cell distribution, cell viability, differentiation and pharmacokinetic plausibility. A transparent decision framework is proposed to distinguish true gamma-globin reactivation from cytotoxic stress, nonspecific differentiation and assay interference.*

Keywords: fetal hemoglobin; gamma-globin; sickle cell disease; beta-thalassemia; BCL11A; hydroxyurea; epigenetic therapy; gene editing; pharmacological induction.



DOI: 10.48175/IJARSCT-37819

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

I. INTRODUCTION

Fetal hemoglobin induction has become one of the most durable therapeutic ideas in beta-hemoglobinopathy research. The concept is attractive because it acts upstream of many disease manifestations: HbF reduces the effective concentration of polymer-forming HbS in sickle cell disease and provides gamma chains that can partner with excess alpha chains in beta-thalassemia [1,2]. Unlike approaches that only manage downstream complications, HbF induction addresses the globin imbalance that drives cellular pathology.

The clinical relevance of HbF is supported by several independent observations. Individuals with hereditary persistence of fetal hemoglobin can remain relatively protected despite carrying pathogenic beta-globin alleles. Hydroxyurea improves outcomes in many patients through mechanisms that include HbF induction. More recently, gene-editing strategies that disrupt fetal-globin repression have shown that adult hematopoiesis can be reprogrammed toward clinically meaningful HbF production [3,6,27,28].

Despite this strong biological rationale, pharmacological HbF induction remains challenging. The same compound can influence proliferation, differentiation, stress signaling and cell survival, making it difficult to determine whether HbF has been selectively reactivated or merely enriched in surviving cells. Published studies also differ substantially in model systems, exposure durations and assays, which complicates comparison. This review therefore synthesizes candidate classes, mechanistic biomarkers, safety considerations and quality requirements for future HbF-inducer evaluation.

The continuing interest in HbF induction also reflects an access issue. Curative or near-curative therapies require advanced infrastructure, whereas oral or otherwise scalable pharmacological agents could reach a wider population if they show durable benefit and acceptable safety. This is particularly relevant for countries with a high burden of hemoglobinopathies and uneven access to specialized transplant or gene-therapy centers.

Another reason for renewed attention is the expanding understanding of globin regulation. The field has moved from empirical observations to a clearer map of repressors, enhancers, chromatin loops and signaling pathways. This knowledge supports mechanism-informed drug selection rather than random screening alone.

II. BIOLOGICAL BASIS OF HBF PROTECTION

Adult hemoglobin A contains two alpha and two beta chains, while fetal hemoglobin contains two alpha and two gamma chains. Developmental switching from HBG1/HBG2 to HBB occurs during late gestation and early infancy through coordinated changes in transcription factors, chromatin state and enhancer-promoter interactions. Low residual HbF persists in a subset of adult red cells known as F-cells [1,27].

In sickle cell disease, deoxygenated HbS polymerizes after a delay time, distorting the red-cell membrane and promoting dehydration, hemolysis, adhesion and vaso-occlusion. HbF does not participate in HbS polymerization and can prolong the delay before sickling. Protection depends not only on total HbF percentage but also on how HbF is distributed across cells. A moderate pancellular increase may protect more red cells than the same average HbF concentrated in a small subset [1,7,31].

In beta-thalassemia, insufficient beta-globin production leaves excess alpha chains, which precipitate in erythroid precursors and damage membranes. Gamma-globin reactivation can improve chain balance by forming HbF, thereby supporting erythroid survival. However, benefit depends on genotype, degree of ineffective erythropoiesis, erythroid maturation and whether enough mature cells are produced to alter clinical requirements [2,30].

The F-cell concept is central to interpretation. Two patients may have the same total HbF percentage but different cellular distribution. If HbF is confined to a small fraction of cells, many erythrocytes remain vulnerable to sickling. If HbF is distributed more evenly, a larger fraction of cells may resist polymerization during deoxygenation. Thus, both average HbF and per-cell distribution matter.

The protective threshold is not universal. It varies with genotype, baseline anemia, alpha-thalassemia coinheritance, red-cell hydration, inflammation, transfusion history and organ status. For this reason, pharmacological screening should not overstate clinical implications from a fixed laboratory threshold.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2



Figure 2. Schematic difference between normal and sickled red-cell morphology.

III. REGULATORY NETWORK OF THE GLOBIN SWITCH

The fetal-to-adult globin switch is controlled by a layered regulatory network. BCL11A is a central fetal-globin repressor, while KLF1 supports the adult erythroid program and contributes to BCL11A expression. ZBTB7A/LRF and SOX6 add partly independent repression, and NuRD-associated factors, DNA methylation, histone deacetylation and histone methylation stabilize the adult state [7-10,28].

Chromatin organization is equally important. The locus control region interacts with globin promoters in a developmental-stage-specific manner, and forced chromatin looping can reactivate fetal-globin transcription. These findings explain why epigenetic agents, transcription-factor modulators and genome-editing strategies can all converge on HbF induction through different entry points [32,33].

For pharmacological evaluation, this complexity is both an opportunity and a challenge. Multiple pathways can be targeted, but a change in one transcript does not establish direct target engagement. A robust interpretation requires HbF protein, HBG transcription, erythroid differentiation, cell viability and relevant repressor markers to be assessed together.

KLF1 illustrates the complexity of the network. It supports adult beta-globin expression and also influences BCL11A, meaning that reducing one pathway may have consequences for erythroid maturation. Similarly, LRF and SOX6 can repress HBG independently of BCL11A, so incomplete response to one strategy may reflect parallel repression.

Epigenetic marks provide memory to the adult globin state. DNA methylation and repressive histone modifications can maintain HBG silencing even when a single transcription factor is modified. This explains why combinations may be attractive, but it also explains why combinations can produce broad and unpredictable effects.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2



Figure 3. Regulatory network controlling the fetal-to-adult globin switch.

IV. ESTABLISHED PHARMACOLOGICAL INDUCER: HYDROXYUREA

Hydroxyurea is the reference drug for pharmacological HbF induction. Its clinical benefits include reduced painful crises and other complications in sickle cell disease when used with appropriate monitoring. Mechanistically, hydroxyurea inhibits ribonucleotide reductase, alters erythroid kinetics and may influence nitric-oxide signaling, stress erythropoiesis and fetal-globin regulatory pathways [3-5].

The limitations of hydroxyurea are clinically important. Response is variable, dose escalation requires monitoring, myelosuppression can limit therapy and adherence strongly influences outcomes. These limitations do not reduce the importance of hydroxyurea; instead, they define the benchmark for new inducers. A new agent should either improve HbF response, reduce toxicity, complement hydroxyurea or serve patients who cannot achieve adequate benefit from existing treatment [3,20].

From a research perspective, hydroxyurea is valuable because it provides both a biological and analytical reference. If an assay cannot detect a hydroxyurea-associated direction of effect under optimized conditions, the model or assay should be questioned before interpreting newer candidates.

Hydroxyurea response is also a reminder that pharmacodynamics and adherence are linked. A drug may be effective in principle but fail in practice if monitoring is burdensome, adverse effects are poorly managed or patients do not receive consistent dose optimization.

V. EPIGENETIC AND CHROMATIN-DIRECTED APPROACHES

DNMT inhibitors can reactivate gamma-globin by reducing methylation-associated repression. HDAC inhibitors and short-chain fatty acids can create a more permissive chromatin state, while G9a/EHMT and LSD1-related pathways target histone methylation mechanisms that support fetal-globin silencing [15,16,34].

These agents provide strong proof of principle but can affect many genes and cellular processes. Broad epigenetic activity may produce HbF induction together with cytotoxicity, differentiation arrest or genomic instability. Therefore, a non-cytotoxic window is essential. HbF detected only at concentrations causing major cell loss should not be considered a desirable pharmacological response without additional evidence.

Chromatin-directed candidates are best evaluated using a tiered strategy: first define viability and morphology, then measure HbF protein and HBG expression, and finally investigate repressor occupancy or chromatin changes if resources permit. This avoids overinterpreting a molecular signal before the cellular context is established.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

DNMT inhibitors are especially powerful conceptually because methylation has long been associated with developmental globin silencing. However, demethylating agents may alter many genomic regions. The challenge is to achieve enough HBG activation without unacceptable marrow or systemic toxicity.

HDAC-related and butyrate-related approaches show how chromatin accessibility can modify globin expression. Their practical development has been limited by pharmacokinetic persistence, tolerability and nonspecific transcriptional effects, but they remain important proof-of-principle tools.

Histone methylation targets such as G9a/EHMT connect fetal-globin repression with specific chromatin marks. These pathways may offer greater mechanistic precision than broad chromatin relaxers, but selectivity and repeated-dose safety remain decisive.

Table 1. Chromatin-directed HbF-inducing strategies.

Class	Representative examples	Main rationale	Key limitation
DNMT-related	Decitabine, azacitidine derivatives	Reduce methylation-associated HBG repression	Broad genomic effects and stability issues
HDAC/short-chain fatty acid	Butyrate derivatives	Open chromatin and support gamma-globin transcription	Short persistence and nonspecific effects
G9a/EHMT inhibition	UNC0638-like probes	Alter H3K9 methylation and chromatin looping	Selectivity and long-term safety
LSD1-related	Tranylcypromine-like probes	Modify histone demethylation pathways	Off-target and hematologic toxicity

VI. IMMUNOMODULATORY, METABOLIC AND STRESS-SIGNALING AGENTS

Immunomodulatory drugs such as pomalidomide and thalidomide have shown hematologic activity, but their reproductive, neurologic and thrombotic risks are decisive translational constraints. These agents are useful mechanistic probes, but clinical application requires strict risk control and careful patient selection [13,35].

Metformin has attracted interest because of links between metabolic signaling, FOXO3 and fetal-globin expression. Its human pharmacology is well known, making it appealing for repurposing, but active in vitro concentrations must be compared with achievable unbound exposure. Antioxidant or metabolic effects alone do not demonstrate HBG activation [11].

Stress-signaling approaches, including salubrinal-associated pathways and PGC-1alpha-linked mechanisms, highlight the relationship between cellular stress, translation and erythroid programming [18,19,46]. The key translational question is whether controlled stress signaling can increase HbF without excessive growth inhibition or marrow toxicity.

The metabolic class is attractive because some agents already have extensive clinical experience in other diseases. However, repurposing cannot rely on approval history alone. The concentration required for HbF induction must be compared with achievable human exposure, and disease-specific safety must be considered.

Stress-signaling agents create a difficult interpretive boundary. Mild stress may activate adaptive programs that include HbF, while severe stress may simply kill sensitive cells or arrest proliferation. This makes matched viability and morphology data indispensable.

Immunomodulatory agents also demonstrate that efficacy and development suitability can diverge. A compound may increase HbF in progenitors but remain unsuitable for broad chronic use because of pregnancy risk, thrombosis, neuropathy or immune effects.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

VII. NATURAL PRODUCTS AND FORMULATION-AWARE INTERPRETATION

Natural compounds may modulate oxidative stress, inflammatory signaling, chromatin and erythroid differentiation. Curcumin is frequently discussed because it affects multiple biological pathways, but poor solubility, limited systemic bioavailability, variable purity and optical interference complicate interpretation. Natural-product studies therefore need strict compound characterization and orthogonal assay confirmation.

A natural candidate should be tested with compound-only blanks, direct cell counting and a viability method not distorted by color or redox activity. It should also be evaluated for solubility, precipitation and stability in culture medium. Without these controls, an apparent HbF signal may reflect analytical interference rather than true gamma-globin reactivation.

Natural products should not be dismissed, but they require the same or greater analytical rigor as synthetic compounds. Batch-to-batch variation, degradation products and multiple constituents can make mechanistic interpretation difficult unless the test material is well characterized.

Formulation can convert a weak laboratory candidate into a more testable drug-delivery problem. If a compound has plausible biology but poor solubility, nanoformulation, complexation or prodrug strategies may be considered before final rejection. However, formulation should not be used to rescue a candidate whose HbF signal is caused by assay interference.

VIII. GENE THERAPY AND GENOME EDITING AS BIOLOGICAL VALIDATION

Cell and gene therapies have changed the HbF field by demonstrating that durable reprogramming of adult hematopoiesis is possible. CRISPR/Cas9 editing of regulatory elements associated with BCL11A can increase HbF, and lentiviral approaches can introduce functional anti-sickling hemoglobin. These therapies validate the target pathway, but they do not eliminate the need for pharmacological strategies [6,21].

The U.S. FDA approved Casgevy and Lyfgenia as the first cell-based gene therapies for sickle cell disease in patients aged 12 years and older in December 2023, with Casgevy being the first FDA-approved treatment to use CRISPR/Cas9 genome-editing technology [21]. The FDA Casgevy product page now lists treatment of patients aged 2 years and older with sickle cell disease with recurrent vaso-occlusive crises and transfusion-dependent beta-thalassemia [22].

Advanced therapies require stem-cell collection, specialized manufacturing, myeloablative conditioning, hospitalization and long-term follow-up. For many settings, especially where resources are limited, scalable pharmacological agents remain important as adjuncts, bridges, combination partners or alternatives for patients who cannot access curative procedures.

The success of genetic approaches reinforces the centrality of BCL11A and related regulatory circuits. It also defines a high bar for pharmacology: reversible drugs may not match the magnitude of one-time editing, but they may offer accessibility, adjustability and combination flexibility.

Long-term follow-up remains essential for advanced therapies because conditioning, engraftment, off-target risks and durability must be understood over years. Pharmacological programs can learn from this emphasis on long-term safety by including early repeated-dose and marrow-toxicity considerations.

IX. ASSAY DESIGN AND QUALITY REQUIREMENTS

HbF-inducer evaluation should not rely on a single endpoint. Bulk HbF can be measured by ELISA or HPLC, while intracellular flow cytometry provides F-cell proportion and per-cell signal. HBG1/HBG2 qRT-PCR detects transcriptional activation, and differentiation markers distinguish selective induction from broader erythroid maturation. Viability and morphology must be measured in the same exposure window.

Critical variables include cell identity, passage number, baseline HbF, seeding density, serum lot, solvent percentage, exposure time, compound stability, RNA quality, reference-gene stability and instrument calibration. These variables should be prospectively controlled using acceptance criteria. A failed run should be repeated rather than made acceptable through selective exclusion of inconsistent data [23,24].

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

Quality-by-Design principles are useful because they convert a complex biological assay into a traceable decision system. Critical material attributes, critical process parameters and critical analytical attributes can be identified before results are interpreted. This approach improves reproducibility and strengthens the evidence needed for candidate progression.

A useful screening platform should include system suitability before candidate interpretation. Positive-control performance, vehicle tolerance and acceptable RNA quality are not administrative details; they determine whether the data can support any conclusion.

Standardization also improves comparability across laboratories. Reporting seeding density, serum lot, exposure time, antibody clone, primer sequences and normalization strategy allows another group to repeat the experiment. Without such details, promising results may be difficult to reproduce.

The minimum evidence package for progression should include at least one protein-level HbF endpoint, one transcript-level HBG endpoint, cell-health evidence, and a statement about exposure plausibility. More complex mechanisms can be pursued after this minimum package is satisfied.

X. CANDIDATE RANKING AND TRANSLATIONAL DECISION LOGIC

A practical ranking algorithm should integrate HbF/F-cell efficacy, HBG induction, viability, morphology, mechanistic coherence, dose-response behavior, reproducibility and feasibility. Weighting should favor coherent multi-endpoint responses over isolated high signals. A compound that increases HbF modestly while preserving cells may be more valuable than one that produces a large signal at toxic concentrations.

Go/no-go decisions should be transparent. A candidate should progress when it shows reproducible HbF/HBG induction within a viable concentration range and has plausible exposure or formulation options. It should be reformulated when solubility or stability prevents interpretation. It should be stopped when activity is inseparable from cytotoxicity, assay interference or unrealistic exposure.

Combination therapy is a reasonable future direction, especially when mechanisms differ. However, combination studies should only follow single-agent dose-response work. Proper reference models and matched vehicle controls are needed to distinguish additivity, synergy and toxicity.

A ranked table is useful only if the inputs are credible. Scores should not hide failed controls, missing repeats or unresolved interference. Therefore, an evidence-grade label can accompany each score, distinguishing confirmed, provisional, exploratory and uninterpretable findings.

Safety should be considered early. A candidate intended for lifelong or repeated use in young populations cannot be assessed solely by acute cell viability. Genotoxicity, reproductive safety, immunologic effects, hepatic metabolism and interactions with transfusion or chelation therapy may all matter.

Table 2. Translational decision pathway for hbf-inducer candidates.

Decision	Criteria	Recommended next action
Progress	Reproducible HbF/HBG induction with preserved viability	Confirm in adult-like erythroid system
Reformulate	Signal limited by solubility, precipitation or instability	Develop formulation and repeat assay
Mechanistic follow-up	HbF and transcript signal coherent but target uncertain	Add protein/chromatin assays
Stop	Activity inseparable from cytotoxicity or interference	Do not progress without new rationale

XI. LIMITATIONS AND FUTURE PERSPECTIVES

The HbF field faces several recurring limitations. Many studies use transformed cell lines that do not fully mimic adult erythropoiesis. Some measure total hemoglobinization without separating HbF-specific induction. Others lack compound-interference controls or do not report negative findings. These weaknesses can exaggerate apparent promise.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

Future research should prioritize adult-like erythroid models, standardized assay conditions, transparent negative reporting, pharmacokinetic plausibility and independent replication. Integration of transcriptomics, chromatin assays and protein-level HbF measurement may clarify mechanisms, but these advanced methods should complement rather than replace cell health and reproducibility checks.

The eventual therapeutic landscape is likely to include multiple approaches: hydroxyurea for established disease modification, advanced therapies for eligible patients, and new pharmacological agents as adjuncts or alternatives. The most successful small-molecule inducer will be safe for repeated use, feasible to manufacture, compatible with standard care and strong enough to produce clinically meaningful HbF distribution.

Future studies should also include patient diversity. Genetic background, baseline HbF modifiers and disease subtype may influence response. Eventually, pharmacological HbF induction may become a stratified intervention in which patients are selected according to molecular or pharmacodynamic predictors.

Digital morphology, high-content imaging and single-cell assays may improve interpretation by linking HbF induction with cell state. However, technological complexity should not replace basic scientific controls. A simple, well-controlled assay can be more informative than a sophisticated but poorly standardized platform.

XII. CONCLUSION

Pharmacological HbF induction remains a scientifically justified and clinically relevant strategy for beta-hemoglobinopathies. The field has progressed from empirical induction toward mechanism-guided candidate selection, but rigorous assay design is essential. Future candidates should be judged by reproducible HbF and HBG activation, preserved erythroid-cell health, exposure plausibility and transparent decision criteria. A standardized QbD-supported screening platform can help identify compounds worthy of ex vivo, formulation and in vivo development.

The central message is that HbF induction is not a single assay result but a therapeutic logic chain. The chain begins with globin biology, continues through controlled pharmacological testing and ends only when safety, exposure and clinical feasibility are addressed.

XIII. PRACTICAL EVIDENCE MAP FOR FUTURE REVIEW UPDATES

A living review of HbF inducers should separate evidence types. Human clinical outcome data, patient-derived erythroid progenitor studies, transformed cell-line assays, animal models, molecular mechanism papers and formulation studies answer different questions. Combining them into one undifferentiated list can mislead readers by making weak exploratory findings appear equivalent to clinical evidence.

The highest level of support for HbF as a target comes from human genetics, hydroxyurea trials and gene-editing studies. The highest level of support for a specific small molecule requires reproducible activity in relevant erythroid cells, confirmation at the protein and transcript levels, and evidence that the active concentration is compatible with human exposure. Many experimental compounds satisfy the first biological criterion but not the exposure or safety criteria.

Review authors should also distinguish between fetal-globin reactivation and general hemoglobinization. Some agents increase benzidine staining or total hemoglobin without selectively increasing HBG. These findings may still be biologically interesting, but they should not be presented as strong HbF induction unless HbF protein or HBG transcripts are measured directly.

The safety profile of a candidate should be discussed in relation to expected duration of use. A compound that is acceptable for short-term laboratory exposure may be unacceptable for chronic use in children, adolescents or reproductive-age adults. Genotoxicity, teratogenicity, immune effects, thrombosis, marrow suppression and hepatic metabolism should be considered before translational optimism is expressed.

Formulation feasibility deserves a dedicated place in future reviews. Some natural or highly lipophilic agents may require advanced delivery systems before their pharmacology can be evaluated realistically. However, formulation should follow confirmation that the pharmacodynamic signal is genuine and not an artifact of insolubility, turbidity or optical interference.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

The review field would benefit from standardized evidence labels. A compound could be described as clinically established, clinically exploratory, ex vivo supported, cell-line supported, mechanistically plausible or uninterpretable. Such labels help readers identify which candidates are ready for translational development and which remain preliminary tools.

TABLE 3. EVIDENCE GRADING MAP FOR HBF-INDUCER LITERATURE.

Evidence level	Typical source	Strength	Main caution
Clinical established	Hydroxyurea trials and long-term practice	Direct patient relevance	Response variability and monitoring burden
Advanced therapy validation	Gene therapy and genome-editing studies	Strong target validation	Infrastructure and conditioning requirements
Patient-derived ex vivo	Primary erythroid cells from patients	Genotype relevance	Limited availability and variability
Transformed cell-line	K562 or similar models	Screening efficiency	May overestimate or distort response
Mechanistic probe	Chromatin or signaling studies	Pathway insight	Not always drug-like or safe
Formulation concept	Delivery or solubility studies	May improve exposure	Requires confirmed pharmacodynamics

IV. REVIEW-LEVEL RECOMMENDATIONS

First, direct HbF or HBG measurement should be treated as essential. Studies based only on total hemoglobinization, antioxidant activity or improved cell survival should be classified as supportive rather than definitive.

Second, safety and exposure should be integrated early. A pharmacologically interesting concentration that cannot be achieved in humans without toxicity should be described as a mechanistic observation, not as a near-term therapeutic candidate.

Third, comparative studies should use common controls. Hydroxyurea, vehicle, untreated cultures and a relevant mechanistic comparator allow the reader to judge whether a candidate performs meaningfully under standardized conditions.

Fourth, negative and equivocal findings should be published. The field advances when weak candidates are identified and when sources of assay interference are documented. Selective publication of positive signals increases duplication and slows genuine development.

Fifth, the next generation of pharmacological HbF induction should be integrated with precision medicine. Baseline HbF modifiers, genotype, co-inherited alpha-thalassemia, inflammatory state and prior treatment may all influence response. Future trials may need biomarker-guided stratification rather than one-size-fits-all enrollment.

Sixth, pharmacological and genetic approaches should be viewed as complementary. Gene editing validates the target and may offer profound benefit to eligible patients, while drugs may provide scalable, adjustable and combination-friendly options for broader populations.

REFERENCES

1. Bauer DE, Orkin SH. Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr Opin Genet Dev. 2015;33:62-70.
2. Belcher JD, Chen C, Nguyen J, Abdulla F, Zhang P, Nguyen H, et al. Control of oxidative stress and inflammation in sickle cell disease with dimethyl fumarate. Antioxid Redox Signal. 2017;26:748-762.
3. Benz EJ. Hemoglobin switching: mechanisms and therapeutic opportunities. Blood. 2011;118:1793-1802.
4. Boosalis MS, Bandyopadhyay R, Bresnick EH, Pace BS. High-throughput fetal-globin inducers are active in baboons and transgenic mice. PLoS One. 2015;10:e0133194.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

5. Bou-Fakhredin R, De Franceschi L, Motta I, Cappellini MD. Pharmacological induction of fetal hemoglobin in beta-thalassemia and sickle cell disease: an updated perspective. Pharmaceuticals. 2022;15:753.
6. Breda L, Motta I, Lourenco S, Gemmo C, Deng W, Rupon JW, et al. Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers. Blood. 2016;128:1139-1143.
7. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-622.
8. Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O, et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature. 2015;527:192-197.
9. Cappellini MD, Farmakis D, Porter J, Taher A. Guidelines for the management of transfusion dependent thalassaemia. Thalassaemia International Federation. 2021.
10. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332:1317-1322.
11. Dai Y, Chen T, Ijaz H, Cho EH, Steinberg MH, Xu J. Fetal-globin inducers reduce transcriptional repression through distinct mechanisms. Blood Cells Mol Dis. 2016;56:62-69.
12. Deng W, Lee J, Wang H, Miller J, Reik A, Gregory PD, et al. Reactivation of developmentally silenced globin genes by forced chromatin looping. Cell. 2014;158:849-860.
13. Dulmovits BM, Appiah-Kubi AO, Papoin J, Hale J, He M, Al-Abed Y, et al. Pomalidomide reverses gamma-globin silencing through transcriptional reprogramming and enhances fetal hemoglobin. Blood. 2016;127:1481-1492.
14. Forget BG. Molecular basis of hereditary persistence of fetal hemoglobin. Ann N Y Acad Sci. 1998;850:38-44.
15. Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N Engl J Med. 2021;384:252-260.
16. Grevet JD, Lan X, Hamagami N, Edwards CR, Sankaranarayanan L, Ji X, et al. Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells. Science. 2018;361:285-290.
17. Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379:373-383.
18. Hoyer JD, Kroft SH. Color atlas of hemoglobin disorders: a compendium based on proficiency testing. College of American Pathologists. 2003.
19. International Council for Harmonisation. ICH Q14: Analytical procedure development. 2023.
20. International Council for Harmonisation. ICH Q2(R2): Validation of analytical procedures. 2023.
21. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.
22. Khamphikham P, Kheansaard W, Chaichompoo P, Svasti S, Srisawat C, Fucharoen S, et al. High-level fetal haemoglobin induction by pomalidomide in beta-thalassaemia/HbE erythroid progenitors. Br J Haematol. 2020;189:524-536.
23. Krivega I, Byrnes C, de Vasconcellos JF, Lee YT, Kaushal M, Dean A, et al. Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR/gamma-globin looping. Blood. 2015;126:665-672.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^-ΔΔCt method. Methods. 2001;25:402-408.
25. Lopez NH, Cazalla D, Yang M, Francois M, Lee JH, Chang K, et al. Salubrinal induces fetal hemoglobin through stress signaling in human and murine sickle cell models. PLoS One. 2022;17:e0267436.
26. Mabaera R, West RJ, Conine SJ, Macari ER, Boyd CD, Engman CA, et al. A cell stress signaling model of fetal hemoglobin induction: what does not kill red cells may make them express HbF. Exp Hematol. 2008;36:1057-1072.
27. Masuda T, Wang X, Maeda M, Canver MC, Sher F, Funnell AP, et al. Transcription factors LRF and BCL11A independently repress fetal hemoglobin. Science. 2016;351:285-289.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, July 2026
Impact Factor: 8.2

28. Menzel S, Thein SL. Genetic modifiers of fetal haemoglobin in sickle cell disease. Mol Diagn Ther. 2019;23:235-244.
29. Nualkaew T, Siritanaratkul N, Fucharoen S, Svasti S. UNC0638 induces high fetal hemoglobin in beta-thalassemia/HbE erythroid progenitors. Ann Hematol. 2020;99:1599-1608.
30. Ofori-Acquah SF. Balancing efficacy, toxicity and access in sickle cell disease drug development. Br J Haematol. 2020;190:316-327.
31. Pace BS, Liu L, Li B, Makala LH, Miller JL. Benserazide enantiomers induce fetal globin gene expression in erythroid cells. Blood Cells Mol Dis. 2021;87:102525.
32. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376:1561-1573.
33. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74:652-656.
34. Renneville A, Van Galen P, Canver MC, McConkey M, Krill-Burger JM, Dorfman DM, et al. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood. 2015;126:1930-1939.
35. Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322:1839-1842.
36. Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol. 2005;33:259-271.
37. Steinberg MH. Fetal hemoglobin in sickle cell anemia. Blood. 2020;136:2392-2400.
38. Sun Y, Paikari A, Sumazin P, Iyer S, Crosby JR, Ma Y, et al. Pharmacologic induction of PGC-1alpha stimulates fetal haemoglobin expression. Br J Haematol. 2022;197:742-754.
39. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391:155-167.
40. Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016;127:810-819.
41. Thein SL. Molecular basis of beta thalassemia and potential therapeutic targets. Blood Cells Mol Dis. 2018;70:54-65.
42. U.S. Food and Drug Administration. CASGEVY product information and indication page. FDA. Content current as of 2026 Jul 2.
43. U.S. Food and Drug Administration. FDA approves first gene therapies to treat patients with sickle cell disease. FDA News Release. 2023 Dec 8.
44. Xu J, Sankaran VG, Ni M, Menne TF, Puram RV, Kim W, et al. Transcriptional silencing of gamma-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev. 2010;24:783-798.
45. Yasara N, Wickramarathne N, Mettananda C, Manamperi A, Premawardhena A, Mettananda S. A comprehensive review of hydroxyurea for beta-haemoglobinopathies. Orphanet J Rare Dis. 2021;16:114.
46. Zhang Y, Paikari A, Sumazin P, Ginter Summarell CC, Crosby JR, Boerwinkle E, et al. Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells. Blood. 2018;132:321-333.